Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma

Digestive Diseases and Sciences

Volumn 60, Issue 4, 2015, Pages 919-928

  Kaibori, Masaki ^a   Shikata, Nobuaki ^b   Sakaguchi, Tatsuma ^a   Ishizaki, Morihiko ^a   Matsui, Kosuke ^a   Iida, Hiroya ^a   Tanaka, Yoshito ^a   Miki, Hirokazu ^a   Nakatake, Richi ^a   Okumura, Tadayoshi ^a   Tokuhara, Katsuji ^a   Inoue, Kentaro ^a   Wada, Jouji ^c   Oda, Michio ^d   Nishizawa, Mikio ^e   Kon, Masanori ^a  

^a KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c Wada Clinic   (Japan)

^d Division of Surgery   (Japan)

^e RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Hepatic resection; Hepatocellular carcinoma; mTOR; Prognostic factor; Raptor; Rictor; Rictor raptor ratio

Indexed keywords

CARRIER PROTEIN; MESSENGER RNA; MTOR PROTEIN, HUMAN; RICTOR PROTEIN, HUMAN; RPTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; HUMAN; JAPAN; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RNA, MESSENGER; TOR SERINE-THREONINE KINASES;

EID: 84934284613     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3417-7     Document Type: Article

References (43)

1. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–285.
2. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK 1979-94. Lancet. 1997;350:1142–1143.
3. EI-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.
4. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.
5. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.
6. Kenerson HL, Aicher LD, True LD, et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002;62:5645–5650.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
8. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–2963.
9. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.
10. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.
11. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–537.
12. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25:6436–6446.
13. Nardella C, Chen Z, Salmena L, et al. Abberrant Rheb-mediated mTOR1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 2008;22:2172–2177.
14. Lu ZH, Shvartsman MB, Lee AY, et al. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 2010;70:3287–3298.
15. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7:1758–1764.
16. Liu L, Li F, Cardelli JA, et al. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene. 2006;25:7029–7040.
17. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature. 2006;441:424–430.
18. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193–198.
19. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–348.
20. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101.
21. Sahin F, Kannangai R, Adegbola O, et al. mTOR and p70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10:8421–8425.
22. Schumacher G, Oidtmann M, Rueggeberg A, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11:1420–1425.
23. Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007;83:425–432.
24. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46:840–848.
25. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972–1983.
26. Strasberg SM, Belghiti J, Clavien PA. The Brisbane 2000 terminology of liver anatomy and resection. Terminology Committee of the International Hepato-Pancreato-Biliary Association. HPB. 2000;2:333–339.
27. Couinaud C, ed. Le Foie: Etudes Anatomiques et Chirurgicales. Paris: Masson; 1957.
28. Woodall CJ, Watt NJ, Clements GB. Simple technique for detecting RNA viruses by PCR in single sections of wax embedded tissue. J Clin Pathol. 1993;46:276–277.
29. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4:135–142.
30. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995–1001.
31. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986–994.
32. Kornmann M, Danenberg KD, Arber N, et al. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 1999;59:3505–3511.
33. Kornmann M, Ishiwata T, Beger HG, et al. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene. 1997;15:1417–1424.
34. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours. 5th ed. New York: Wiley; 1997.
35. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem. 2010;10:571–581.
36. Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013;15:1340–1350.
37. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332:1317–1322.
38. Yu Y, Yoon SO, Poulogiannis G, et al. Quantitative phosphoproteomic analysis identifies the adaptor protein Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332:1322–1326.
39. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205.
40. Trzpis M, McLaughlin PMJ, Leij LMFH, et al. Epithelial cell adhesion molecule. More than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171:386–395.
41. Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target EpCAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94:128–135.
42. Murakata A, Tanaka S, Mogushi K, et al. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg. 2011;253:94–100.
43. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014;20:2072–2079.